Novartis Q3 2025 Investor Presentation

These documents provide an overview of Novartis's Q3 2025 financial results and innovation pipeline, delivered by the Chief Financial Officer and Chief Executive Officer. The financial report highlights key performance indicators, such as a 7% growth in net sales and core operating income (cc) for the quarter, and confirms the 2025 full-year guidance for sales and core operating income. The presentation also details the robust growth of priority brands like Kesimpta and Pluvicto, while noting sales challenges for other products like Entresto due to generic competition, and provides extensive disclosures regarding forward-looking statements, non-IFRS measures, and ongoing legal proceedings. Furthermore, the sources outline Novartis’s clinical trial updates across oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic therapeutic areas, confirming various Phase 3 trials for innovative treatments such as ianalumab, remibrutinib, and zigakibart.